Role of External Vibratory Lithoclast (Lithecbole) in Improving Lower Pole Stone Clearance After Extracorporeal Shock Wave Lithotripsy (ESWL).

Pak J Biol SciSep 12, 2026
Clinical ResearchUrology

Issam Salman Al-Azzawi, Ehab Jasim Mohammad, Waleed Nassar Jaffal et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the efficacy of External Physical Vibration Lithecbole (EPVL) as an adjunct to extracorporeal shock wave lithotripsy (ESWL) in 100 patients with lower pole renal stones. The study found a significantly higher stone-free rate in the ESWL+EPVL group (66%) compared to the ESWL-only group (48%, p = 0.027), suggesting that EPVL may improve stone clearance outcomes.

Key findings

  • The stone-free rate was 66% in the ESWL+EPVL group versus 48% in the ESWL-only group (p = 0.027).
  • Complication rates were low and similar between both groups (p = 0.3).
  • Smaller stone size and lower patient weight were significantly associated with successful stone clearance.

Why it matters

Improving stone clearance rates in patients with lower pole renal stones can enhance treatment outcomes and reduce the need for additional interventions. Understanding adjunctive therapies like EPVL may help clinicians optimize patient management.

Source

PubMed · PMID 42723160

Published in Pak J Biol Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.